ES2523016B1 - Vectores alfavirales y líneas celulares para la producción de proteínas recombinantes - Google Patents

Vectores alfavirales y líneas celulares para la producción de proteínas recombinantes Download PDF

Info

Publication number
ES2523016B1
ES2523016B1 ES201330722A ES201330722A ES2523016B1 ES 2523016 B1 ES2523016 B1 ES 2523016B1 ES 201330722 A ES201330722 A ES 201330722A ES 201330722 A ES201330722 A ES 201330722A ES 2523016 B1 ES2523016 B1 ES 2523016B1
Authority
ES
Spain
Prior art keywords
sequence
gene
polynucleotide
seo
interest
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
ES201330722A
Other languages
English (en)
Spanish (es)
Other versions
ES2523016A1 (es
Inventor
Alejandro ARANDA
Jaione BEZUNARTEA BEZUNARTEA
Cristian Smerdou Picazo
Dámaso MOLERO SÁNCHEZ
Edita Mistiniene
Andreu SOLDEVILA FÁBREGA
Paula SERRANO PÉREZ-NIEVAS
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
3P Biopharmaceuticals SL
Original Assignee
3P Biopharmaceuticals SL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 3P Biopharmaceuticals SL filed Critical 3P Biopharmaceuticals SL
Priority to ES201330722A priority Critical patent/ES2523016B1/es
Priority to ES14801304T priority patent/ES2759916T3/es
Priority to PCT/ES2014/070416 priority patent/WO2014188042A1/fr
Priority to EP14801304.8A priority patent/EP3000890B1/fr
Priority to US14/892,829 priority patent/US10011847B2/en
Publication of ES2523016A1 publication Critical patent/ES2523016A1/es
Application granted granted Critical
Publication of ES2523016B1 publication Critical patent/ES2523016B1/es
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/36011—Togaviridae
    • C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
    • C12N2770/36141—Use of virus, viral particle or viral elements as a vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/30—Vector systems comprising sequences for excision in presence of a recombinase, e.g. loxP or FRT
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
    • C12N2840/203—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
ES201330722A 2013-05-20 2013-05-20 Vectores alfavirales y líneas celulares para la producción de proteínas recombinantes Expired - Fee Related ES2523016B1 (es)

Priority Applications (5)

Application Number Priority Date Filing Date Title
ES201330722A ES2523016B1 (es) 2013-05-20 2013-05-20 Vectores alfavirales y líneas celulares para la producción de proteínas recombinantes
ES14801304T ES2759916T3 (es) 2013-05-20 2014-05-20 Vectores alfavirales y líneas celulares para la producción de proteínas recombinantes
PCT/ES2014/070416 WO2014188042A1 (fr) 2013-05-20 2014-05-20 Vecteurs alpha viraux et lignées cellulaires permettant la production de protéines recombinantes
EP14801304.8A EP3000890B1 (fr) 2013-05-20 2014-05-20 Vecteurs alpha viraux et lignées cellulaires permettant la production de protéines recombinantes
US14/892,829 US10011847B2 (en) 2013-05-20 2014-05-20 Alphaviral vectors and cell lines for producing recombinant proteins

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ES201330722A ES2523016B1 (es) 2013-05-20 2013-05-20 Vectores alfavirales y líneas celulares para la producción de proteínas recombinantes

Publications (2)

Publication Number Publication Date
ES2523016A1 ES2523016A1 (es) 2014-11-20
ES2523016B1 true ES2523016B1 (es) 2015-09-09

Family

ID=51899033

Family Applications (2)

Application Number Title Priority Date Filing Date
ES201330722A Expired - Fee Related ES2523016B1 (es) 2013-05-20 2013-05-20 Vectores alfavirales y líneas celulares para la producción de proteínas recombinantes
ES14801304T Active ES2759916T3 (es) 2013-05-20 2014-05-20 Vectores alfavirales y líneas celulares para la producción de proteínas recombinantes

Family Applications After (1)

Application Number Title Priority Date Filing Date
ES14801304T Active ES2759916T3 (es) 2013-05-20 2014-05-20 Vectores alfavirales y líneas celulares para la producción de proteínas recombinantes

Country Status (4)

Country Link
US (1) US10011847B2 (fr)
EP (1) EP3000890B1 (fr)
ES (2) ES2523016B1 (fr)
WO (1) WO2014188042A1 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020181058A1 (fr) * 2019-03-05 2020-09-10 Massachusetts Institute Of Technology Système de réplicon d'arn lancé par l'adn et ses utilisations
JP2023529892A (ja) 2020-06-09 2023-07-12 イノザイム ファーマ インク． 可溶性ｅｎｐｐ１又はｅｎｐｐ３タンパク質及びその使用
CN112143755A (zh) * 2020-10-19 2020-12-29 深圳市瑞普逊科技有限公司 一种人甲状旁腺激素真核表达重组质粒载体及其构建方法

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0217822B1 (fr) 1985-02-13 1993-05-12 Scios Nova Inc. Promoteur de la metallothioneine-ii humaine dans un systeme mammifere d'expression
US5866755A (en) 1993-06-14 1999-02-02 Basf Aktiengellschaft Animals transgenic for a tetracycline-regulated transcriptional inhibitor
GB9326271D0 (en) 1993-12-23 1994-02-23 Zeneca Ltd Expression of self-processing polyprotein in transgenic plants
ATE496288T1 (de) 1995-10-11 2011-02-15 Luminex Corp Gleichzeitige mehrfachanalyse klinischer proben
IL126418A0 (en) 1996-04-05 1999-05-09 Salk Inst For Biological Studi Hormone-mediated methods for modulating expression of exogenous genes and pharmaceutical compositions for modulating the same
US6451592B1 (en) * 1996-04-05 2002-09-17 Chiron Corporation Recombinant alphavirus-based vectors with reduced inhibition of cellular macromolecular synthesis
JP4383530B2 (ja) 1996-04-05 2009-12-16 ノバルティス バクシンズ アンド ダイアグノスティックス， インコーポレーテッド 細胞巨大分子合成の阻害が減少したアルファウイルスベクター
US6534314B1 (en) 1996-06-14 2003-03-18 Massachusetts Institute Of Technology Methods and compositions for transforming cells
US6057134A (en) 1996-10-07 2000-05-02 Ambion, Inc. Modulating the efficiency of nucleic acid amplification reactions with 3' modified oligonucleotides
EP1009802B1 (fr) 1997-02-12 2004-08-11 Eugene Y. Chan PROCEDES d ANALYSE DES POLYMERES
US6365731B1 (en) 1997-08-06 2002-04-02 Ambion, Inc. Stripping nucleic acids with iodine and sodium thiosulfate
WO1999019515A1 (fr) 1997-10-14 1999-04-22 Luminex Corporation Particules fluorescentes de precision, et procede de fabrication et mode d'utilisation associes
JP4206154B2 (ja) 1997-11-13 2009-01-07 大日本住友製薬株式会社 変異型ｌｏｘＰ配列とその応用
US6451579B1 (en) 1998-07-29 2002-09-17 Invitrogen Corporation Regulated expression of recombinant proteins using RNA viruses
US6458583B1 (en) 1998-09-09 2002-10-01 Agilent Technologies, Inc. Method and apparatus for making nucleic acid arrays
US6461812B2 (en) 1998-09-09 2002-10-08 Agilent Technologies, Inc. Method and multiple reservoir apparatus for fabrication of biomolecular arrays
US6436640B1 (en) 1999-03-18 2002-08-20 Exiqon A/S Use of LNA in mass spectrometry
EP1169458A2 (fr) 1999-04-06 2002-01-09 Oklahoma Medical Research Foundation Methode de selection de variantes de recombinase a specificite modifiee
US6287813B1 (en) 1999-04-23 2001-09-11 Cistronics Cell Technology Gmbh Antibiotic-based gene regulation system
US6465183B2 (en) 1999-07-01 2002-10-15 Agilent Technologies, Inc. Multidentate arrays
US6461816B1 (en) 1999-07-09 2002-10-08 Agilent Technologies, Inc. Methods for controlling cross-hybridization in analysis of nucleic acid sequences
WO2001013120A1 (fr) 1999-08-17 2001-02-22 Luminex Corporation Microparticules produisant plusieurs signaux fluorescents et procedes d'utilisation associes
US7122303B2 (en) 1999-09-17 2006-10-17 Agilent Technologies, Inc. Arrays comprising background features that provide for a measure of a non-specific binding and methods for using the same
US6428957B1 (en) 1999-11-08 2002-08-06 Agilent Technologies, Inc. Systems tools and methods of assaying biological materials using spatially-addressable arrays
AU1647501A (en) * 1999-12-10 2001-06-18 Cytos Biotechnology Ag Replicon based activation of endogenous genes
CA2407050A1 (fr) 2000-04-25 2001-11-01 Chiron Corporation Vecteurs a base d'alphavirus destines a l'infection durable
US6750015B2 (en) 2000-06-28 2004-06-15 Kathryn B. Horwitz Progesterone receptor-regulated gene expression and methods related thereto
CA2459347C (fr) 2001-09-04 2012-10-09 Exiqon A/S Compositions d'acides nucleiques bloques et leurs utilisations
DE10148294C1 (de) 2001-09-29 2003-01-16 Unicor Rohrsysteme Gmbh Formbackenhälfte für einen Corrugator zum Herstellen von Querrippenrohren
AU2003234734A1 (en) 2002-04-29 2003-11-17 Saint Louis University Peptide antagonists of tgf-beta family members and therapeutic uses thereof
ES2304069B1 (es) 2003-08-22 2009-08-12 Proyecto De Biomedicina Cima, S.L. Peptidos con capacidad de unirse al factor transformante de crecimiento beta 1 (tgf-b1).
ES2292271B1 (es) 2004-05-20 2009-02-16 Proyecto De Biomedicina Cima, S.L. Un vector hibrido adenovirus-alfavirus para la administracion eficaz y expresion de genes terapeuticos en celulas tumorales.
US7696335B2 (en) 2005-10-13 2010-04-13 Bc Cancer Agency Kits for multiple non-cross reacting recombination reactions utilizing loxP sequences
GR20060100496A (el) * 2006-09-01 2008-04-15 Παρθενιος Μπουλικας ΛΙΠΟΣΩΜΑΤΙΚΑ ΕΓΚΑΨΥΛΙΩΜΕΝΟΙ ΦΟΡΕΙΣ-ΥΒΡΙΔΙΟΥ ΑΔΕΝΟΙΟΥ - ΙΟΥ SEMLIKI FOREST (SFV), ΠΟΥ ΦΕΡΕΙ ΚΑΤΑΣΚΕΥΑΣΜΑΤΑ RNAi ΚΑΙ ΘΕΡΑΠΕΥΤΙΚΑ ΓΟΝΙΔΙΑ ΠΟΥ ΧΡΗΣΙΜΟΠΟΙΟΥΝΤΑΙ ΕΝΑΝΤΙΟΝ ΣΤΟΧΩΝ ΚΑΡΚΙΝΟΥ ΚΑΙ ΑΛΛΩΝ ΑΣΘΕΝΕΙΩΝ
AU2007327452B2 (en) 2006-11-28 2012-08-30 Proyecto De Biomedicina Cima, S.L. Viral vector and its applications
WO2011064437A2 (fr) * 2009-11-26 2011-06-03 Proyecto De Biomedicina Cima, S.L. Vecteurs viraux et procédés utiles dans la préparation de gdnf
WO2012001196A2 (fr) * 2010-06-28 2012-01-05 Proyecto De Biomedicina Cima, S.L. Vecteurs alphaviraux et leur utilisation pour l'expression de gènes hétérologues

Also Published As

Publication number Publication date
EP3000890B1 (fr) 2019-08-14
EP3000890A1 (fr) 2016-03-30
US10011847B2 (en) 2018-07-03
ES2759916T3 (es) 2020-05-12
EP3000890A4 (fr) 2017-02-01
WO2014188042A1 (fr) 2014-11-27
US20160208286A1 (en) 2016-07-21
ES2523016A1 (es) 2014-11-20

Similar Documents

Publication Publication Date Title
ES2781073T3 (es) Receptores de antígenos quiméricos del promotor MND
Fussenegger et al. pTRIDENT, a novel vector family for tricistronic gene expression in mammalian cells
JP4307079B2 (ja) マトリックス付着領域およびその使用方法
JP6688297B2 (ja) サイトメガロウイルス抗原を発現する哺乳動物細胞
JP2012235782A (ja) Ｓｏｒｆ構築物並びにポリタンパク質、プロタンパク質及びタンパク質分解による方法を含む複数の遺伝子発現
JP2001519165A (ja) 細胞巨大分子合成の阻害が低減された組換えアルファウイルスベースのベクター
EP0760000A1 (fr) Vecteur d'expression de l'alphavirus
JPH01165395A (ja) 組換えタンパク質発現のための一時発現系
Mielke et al. Stabilized, long-term expression of heterodimeric proteins from tricistronic mRNA
WO2008119827A1 (fr) Produits de synthèse transréplicases
ES2439874T3 (es) Sistema de expresión en eucariotas inducible
ES2523016B1 (es) Vectores alfavirales y líneas celulares para la producción de proteínas recombinantes
US11254935B2 (en) Methods and compositions for use of non-coding RNA in cell culturing and selection
EP2097533B9 (fr) Vecteur viral et ses applications
WO2019129175A1 (fr) Promoteur chimère ayant une activité transcriptionnelle élevée dans des lymphocytes t
EA037273B1 (ru) Экспрессионная кассета
JP5554907B2 (ja) 促進された遺伝子発現能力を伴う新規発現ベクターおよびそれを使用するための方法
Schlatter et al. Modulation of translation‐initiation in CHO‐K1 cells by rapamycin‐induced heterodimerization of engineered eIF4G fusion proteins
Aranda et al. A quick and efficient method to generate mammalian stable cell lines based on a novel inducible alphavirus DNA/RNA layered system
WO2018150345A1 (fr) Vecteur d'expression
Makrides Vectors for gene expression in mammalian cells
CN114729361B (zh) 一种在活化的t细胞中具有高活性的启动子
Boorsma et al. Alphavirus cDNA‐based expression vectors: Effects of RNA transcription and nuclear export
CA2309835A1 (fr) Vecteurs d'alphavirus
JP2016514477A (ja) 哺乳動物細胞内で生物活性タンパク質を発現させるための方法および構築物

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 2523016

Country of ref document: ES

Kind code of ref document: B1

Effective date: 20150909

FD2A Announcement of lapse in spain

Effective date: 20211004